X

Drug Profile

EB 1007

Alternative Names: EB-1007

Latest Information Update: 01 Sep 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eden Biologics
Class Antineoplastics; Immunotherapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Cancer

Highest Development Phases

Preclinical Cancer

Most Recent Events

26 Aug 2021 EB 1007 is available for licensing in World as of 26 Aug 2021. https://www.edenbiologics.com/pipeline-3/
26 Aug 2021 Preclinical trials in Cancer in Taiwan (unspecified route) (Eden Biologics pipeline, August 2021)
19 Feb 2021 JHL Biotech is now called Eden Biologics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com